245 related articles for article (PubMed ID: 23562522)
1. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study.
Segev Y; Iqbal J; Lubinski J; Gronwald J; Lynch HT; Moller P; Ghadirian P; Rosen B; Tung N; Kim-Sing C; Foulkes WD; Neuhausen SL; Senter L; Singer CF; Karlan B; Ping S; Narod SA;
Gynecol Oncol; 2013 Jul; 130(1):127-31. PubMed ID: 23562522
[TBL] [Abstract][Full Text] [Related]
2. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study.
Beiner ME; Finch A; Rosen B; Lubinski J; Moller P; Ghadirian P; Lynch HT; Friedman E; Sun P; Narod SA;
Gynecol Oncol; 2007 Jan; 104(1):7-10. PubMed ID: 16962648
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL;
N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993
[TBL] [Abstract][Full Text] [Related]
4. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
Friebel TM; Domchek SM; Neuhausen SL; Wagner T; Evans DG; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson G; Lynch HT; Tung N; Blum JL; Weitzel J; Rubinstein WS; Ganz PA; Couch F; Rebbeck TR
Clin Breast Cancer; 2007 Dec; 7(11):875-82. PubMed ID: 18269778
[TBL] [Abstract][Full Text] [Related]
5. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
6. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
[TBL] [Abstract][Full Text] [Related]
7. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
[TBL] [Abstract][Full Text] [Related]
8. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
[TBL] [Abstract][Full Text] [Related]
9. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Metcalfe K; Lynch HT; Ghadirian P; Tung N; Olivotto I; Warner E; Olopade OI; Eisen A; Weber B; McLennan J; Sun P; Foulkes WD; Narod SA
J Clin Oncol; 2004 Jun; 22(12):2328-35. PubMed ID: 15197194
[TBL] [Abstract][Full Text] [Related]
10. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
[TBL] [Abstract][Full Text] [Related]
11. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
Domchek SM; Friebel TM; Neuhausen SL; Wagner T; Evans G; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson GE; Van't Veer L; Lynch HT; Olopade OI; Weber BL; Rebbeck TR
Lancet Oncol; 2006 Mar; 7(3):223-9. PubMed ID: 16510331
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
[TBL] [Abstract][Full Text] [Related]
14. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
[TBL] [Abstract][Full Text] [Related]
15. Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.
Harvey SL; Milne RL; McLachlan SA; Friedlander ML; Birch KE; Weideman P; ; Goldgar D; Hopper JL; Phillips KA
Breast Cancer Res Treat; 2011 Dec; 130(3):1057-61. PubMed ID: 21850394
[TBL] [Abstract][Full Text] [Related]
16. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers.
Fakkert IE; Mourits MJ; Jansen L; van der Kolk DM; Meijer K; Oosterwijk JC; van der Vegt B; Greuter MJ; de Bock GH
Cancer Prev Res (Phila); 2012 Nov; 5(11):1291-7. PubMed ID: 23009828
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.
Vicus D; Finch A; Rosen B; Fan I; Bradley L; Cass I; Sun P; Karlan B; McLaughlin J; Narod SA;
Gynecol Oncol; 2010 Aug; 118(2):155-9. PubMed ID: 20452659
[TBL] [Abstract][Full Text] [Related]
18. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
[TBL] [Abstract][Full Text] [Related]
19. Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers.
Reitsma W; Mourits MJ; de Bock GH; Hollema H
Mod Pathol; 2013 Apr; 26(4):572-8. PubMed ID: 23080033
[TBL] [Abstract][Full Text] [Related]
20. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
Metcalfe KA; Birenbaum-Carmeli D; Lubinski J; Gronwald J; Lynch H; Moller P; Ghadirian P; Foulkes WD; Klijn J; Friedman E; Kim-Sing C; Ainsworth P; Rosen B; Domchek S; Wagner T; Tung N; Manoukian S; Couch F; Sun P; Narod SA;
Int J Cancer; 2008 May; 122(9):2017-22. PubMed ID: 18196574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
